Bigger Money: Private Equity Grabs European VC
Deals show large investors’ appetite for early-stage biotech, but can VC and PE rub along?
You may also be interested in...
Over 100 biopharma companies piled onto public markets in 2021, raising a combined $21bn. A sharp cool off has left many trading well below their listing price. What does it mean for biotech financing in 2022?
EQT and Goldman Sachs to pay $8.5bn in Parexel’s second private equity buyout in four years.
The UK-headquartered life sciences investment firm has comfortably exceeded its target of $350m for a fund dedicated to taking on late-stage products, incurring all the clinical and regulatory risk and receiving a pre-negotiated return once the drug is approved.